Ron Frieson - 01 Nov 2021 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
Director
Signature
/s/ Carolyn Rucci, attorney-in-fact for Ronald E. Frieson
Issuer symbol
AKBA
Transactions as of
01 Nov 2021
Net transactions value
$0
Form type
4
Filing time
03 Nov 2021, 16:47:43 UTC
Next filing
09 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +80,200 $0.000000 80,200 01 Nov 2021 Common Stock 80,200 $3.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter